Ariel Investments, an investment management company, released its “Ariel Fund” fourth-quarter 2025 investor letter. A copy of ...

Dental products company Dentsply Sirona (NASDAQ:XRAY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.2 ...

Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

Dental products company Dentsply Sirona (NASDAQ:XRAY) will be reporting earnings tomorrow after the bell. Here’s what to look ...

DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled ...

Return on Assets (ROA): Dentsply Sirona's ROA is below industry standards, pointing towards difficulties in efficiently ...

As of April 1, Burkhart Dental Supply will represent Dentsply Sirona’s full portfolio of dental technology solutions in addition to preventive ...

Despite reporting solid operational growth, shares of dental technology leader Dentsply Sirona closed the trading week on a softer note, drawing investor attention to key technical levels. The recent ...

Management reaffirmed the full-year 2025 guidance for organic sales to decline by 2%-4% and adjusted EPS to remain in the range of $1.80 to $2. Reported sales guidance was revised upward to $3.6 ...

Dentsply Sirona logged a narrower loss in its fourth quarter and launched a restructuring initiative to drive profitable growth. The dental company recorded a fourth-quarter net loss of $146 million, ...

DENTSPLY SIRONA Inc. XRAY is scheduled to release fourth-quarter 2025 results on Feb. 26, after market close. In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate ...

Sirona is not beating around the bush: the company has had a difficult time selling its diabetes med and is now “less confident” it will score a licensing deal. The candid about-face came in a ...